Vireo Health International Inc. (OTCMKTS: VREOF) Launches Ground Cannabis Flower In Its Dispensaries In New York

Vireo Health International Inc. (OTCMKTS: VREOF) has launched its first line of ground medical cannabis flower in New York. The company will expand its new line of ground medical flower to four strains and will be available in 3.5 g and 7g jars at all Vireo Health dispensaries in New York and through home delivery. 

New ground cannabis features Indica and Sativa blend

The expanded line features Sativa, Indica, and hybrid strains such as Wedding cake, Killer Kush, and Kosher-approved Tangie Kush. By September, the company expects to expand its ground flower line to include up to 20 different cannabis strains. Currently, Ground flower is permitted by the New York Health Department for medical use by patients to vaporize. 

CEO and Chairman Dr. Kyle Kingsley said they are delighted to launch a full medical cannabis flower product line for patients in New York. He added that allowing medical cannabis sale in its natural form as dried flower is an effective way of reducing the medical cannabis cost. Kingsley said that with the dried cannabis flower offering, they would enhance patient accessibility affordability and expand its offerings. As a result, this will help the current medical cannabis patients and make the program attractive to New Yorkers. 

All Vireo Health dispensaries in New York to sell ground cannabis 

Following the ground flower cannabis products launch, the company will now have ground cannabis flower from three registered growers at its four Vireo dispensaries in White Plains, Albany, Queens, and Binghamton as home delivery. This will be the largest ground flower products selection at any dispensary in New York. 

Dr. Stephen Dahmer, Vireo Health’s Chief Medical Officer, said that allowing ground flower into the medical cannabis program will help protect public safety and health by minimizing the number of people purchasing illegal cannabis. He added that patients who don’t afford the state’s program are always looking to illicit markets for their medical cannabis. As a result, this leads to vulnerable patients using untested and unsafe products.